PHASE 2 STUDY OF AZD2014, A DUAL MTORC1/MTORC1 INHIBITOR, FOR NF2 PATIENTS WITH PROGRESSIVE OR SYMPTOMATIC MENINGIOMAS

$1,121,983FY2016Department of the ArmyDOD

The General Hospital Corporation

Investigators